BACKGROUND AND PURPOSE: The anticancer drugs doxorubicin and bleomycin are well-known for their oxidative stress-mediated side effects in heart and lung, respectively. It is frequently suggested that iron is involved in doxorubicin and bleomycin toxicity. We set out to elucidate whether iron chelation prevents the oxidative stress-mediated toxicity of doxorubicin and bleomycin and whether it affects their antiproliferative/proapoptotic effects. EXPERIMENTAL APPROACH: Cell culture experiments were performed in A549 cells. Formation of hydroxyl radicals was measured in vitro by electron paramagnetic resonance (EPR). We investigated interactions between five iron chelators and the oxidative stress-inducing agents (doxorubicin, bleomycin and H(2)O(2)) by quantifying oxidative stress and cellular damage as TBARS formation, glutathione (GSH) consumption and lactic dehydrogenase (LDH) leakage. The antitumour/proapoptotic effects of doxorubicin and bleomycin were assessed by cell proliferation and caspase-3 activity assay. KEY RESULTS: All the tested chelators, except for monohydroxyethylrutoside (monoHER), prevented hydroxyl radical formation induced by H(2)O(2)/Fe(2+) in EPR studies. However, only salicylaldehyde isonicotinoyl hydrazone and deferoxamine protected intact A549 cells against H(2)O(2)/Fe(2+). Conversely, the chelators that decreased doxorubicin and bleomycin-induced oxidative stress and cellular damage (dexrazoxane, monoHER) were not able to protect against H(2)O(2)/Fe(2+). CONCLUSIONS AND IMPLICATIONS: We have shown that the ability to chelate iron as such is not the sole determinant of a compound protecting against doxorubicin or bleomycin-induced cytotoxicity. Our data challenge the putative role of iron and hydroxyl radicals in the oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin and have implications for the development of new compounds to protects against this toxicity.

Department of Biochemical Sciences Charles University Prague Hradec Králové Czech Republic

Zobrazit více v PubMed

Abou El Hassan MA, Rabelink MJ, Van der Vijgh WJF, Bast A, Hoeben RC. A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro. Br J Cancer. 2003a;89:2140–2146. PubMed PMC

Abou El Hassan MA, Verheul HM, Jorna AS, Schalkwijk C, Van Bezu J, Van der Vijgh WJF, et al. The new cardioprotector monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro. Br J Cancer. 2003b;89:357–362. PubMed PMC

Azambuja E, Fleck JF, Batista RG, Menna Barreto SS. Bleomycin lung toxicity: who are the patients with increased risk. Pulm Pharmacol Ther. 2005;18:363–366. PubMed

Baker E, Richardson D, Gross S, Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology. 1992;15:492–501. PubMed

Baker E, Vitolo ML, Webb J. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol. 1985;34:3011–3017. PubMed

Bowler RP, Nicks M, Warnick K, Crapo JD. Role of extracellular superoxide dismutase in bleomycin-induced pulmonary fibrosis. Am J Physiol-Lung C. 2002;282:L719–L726. PubMed

Brown RE, Jarvis KL, Hyland KJ. Protein measurement using bicinchoninic acid: elimination of interfering substances. Anal Biochem. 1989;180:136–139. PubMed

Burke BE, Gambliel H, Olson RD, Bauer FK, Cusack BJ. Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. Br J Pharmacol. 2000;131:1–4. PubMed PMC

Buss JL, Hasinoff BB. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions. 1993;40:86–95. PubMed

Buss JL, Neuzil J, Gellert N, Weber C, Ponka P. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties. Biochem Pharmacol. 2003;65:161–172. PubMed

Buss JL, Neuzil J, Ponka P. Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs. Arch Biochem Biophys. 2004;421:1–9. PubMed

Cabantchik ZI, Glickstein H, Milgram P, Breuer W. A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells. Anal Biochem. 1996;233:221–227. PubMed

Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005–1024. PubMed

De Franceschi L, Turrini F, Honczarenko M, Ayi K, Rivera A, Fleming MD, et al. In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica. 2004;89:1287–1298. PubMed

Den Hartog GJM, Haenen GRMM, Boven E, Van der Vijgh WJF, Bast A. Lecithinized copper, zinc-superoxide dismutase as a protector against doxorubicin-induced cardiotoxicity in mice. Toxicol Appl Pharm. 2004;194:180–188. PubMed

El-Medany A, Hagar HH, Moursi M, At Muhammed R, El-Rakhawy FI, El-Medany G. Attenuation of bleomycin-induced lung fibrosis in rats by mesna. Eur J Pharmacol. 2005;509:61–70. PubMed

Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727–741. PubMed

Haenen GRMM, Jansen FP, Bast A. The antioxidant properties of five O-(β-hydroxyethyl)-rutosides of the flavonoid mixture Venoruton. Phlebology Suppl. 1993;1:10–17.

Hasinoff BB. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc Toxicol. 2002;2:111–118. PubMed

Hasinoff BB. Dexrazoxane use in the prevention of anthracycline extravasation injury. Future Oncol. 2006;2:15–20. PubMed

Hasinoff BB, Abram ME, Barnabe N, Khelifa T, Allan WP, Yalowich JC. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001;59:453–461. PubMed

Hasinoff BB, Schnabl KL, Marusak RA, Patel D, Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol. 2003;3:89–99. PubMed

Hasinoff BB, Yalowich JC, Ling Y, Buss JL. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs. 1996;7:558–567. PubMed

Herman EH, Hasinoff BB, Zhang J, Raley LG, Zhang TM, Fukuda Y, et al. Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology. 1995;98:163–175. PubMed

Hermes-Lima M, Ponka P, Schulman HM. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate. Biochim Biophys Acta. 2000;1523:154–160. PubMed

Hoke EM, Maylock CA, Shacter E. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic Biol Med. 2005;39:403–411. PubMed

Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. Cardiovasc Res. 2000;47:529–536. PubMed

Hoy T, Humphrys J, Jacobs A, Williams A, Ponka P. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol. 1979;43:443–449. PubMed

Kartikasari AE, Georgiou NA, Visseren FL, Van Kats-Renaud H, Van Asbeck BS, Marx JJ. Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:2257–2262. PubMed

Keizer HG, Pinedo HM, Schuurhui GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47:219–231. PubMed

Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol. 2003;63:849–861. PubMed

Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res. 2000;6:3680–3686. PubMed

Larramendy ML, Lopez-Larraza D, Vidal-Rioja L, Bianchi NO. Effect of the metal chelating agent o-phenanthroline on the DNA and chromosome damage induced by bleomycin in Chinese hamster ovary cells. Cancer Res. 1989;49:6583–6586. PubMed

Lepage G, Munoz G, Champagne J, Roy CC. Preparative steps necessary for the accurate measurement of malondialdehyde by high-performance liquid chromatography. Anal Biochem. 1991;197:277–283. PubMed

Lovejoy DB, Richardson DR. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem. 2003;10:1035–1049. PubMed

Lyman S, Taylor P, Lornitzo F, Wier A, Stone D, Antholine WE, et al. Activity of bleomycin in iron- and copper-deficient cells. Biochem Pharmacol. 1989;38:4273–4282. PubMed

Malisza KL, Hasinoff BB. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals. Arch Biochem Biophys. 1995;316:680–688. PubMed

Manoury B, Nenan S, Leclerc O, Guenon I, Boichot E, Planquois JM, et al. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir Res. 2005;6:11. PubMed PMC

Marty M, Espie M, Llombart A, Monnier A, Rapoport BL, Stahalova V. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17:614–622. PubMed

Minotti G, Cairo G, Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song. FASEB J. 1999;13:199–212. PubMed

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185–229. PubMed

Mir LM, Tounekti O, Orlowski S. Bleomycin: Revival of an old drug. Gen Pharmacol. 1996;27:745–748. PubMed

Mladenka P, Simunek T, Hubl M, Hrdina R. The role of reactive oxygen and nitrogen species in cellular iron metabolism. Free Radic Res. 2006;40:263–272. PubMed

Persson HL, Yu Z, Tirosh O, Eaton JW, Brunk UT. Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Radic Biol Med. 2003;34:1295–1305. PubMed

Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 1979;97:317–321. PubMed

Sargent JM, Williamson CJ, Yardley C, Taylor CG, Hellmann K. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. Br J Cancer. 2001;84:959–964. PubMed PMC

Schroterova L, Kaiserova H, Baliharova V, Velik J, Gersl V, Kvasnickova E. The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53:683–691. PubMed

Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, et al. SIH – a novel lipophilic iron chelator – protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol. 2005a;39:345–354. PubMed

Simunek T, Klimtova I, Kaplanova J, Sterba M, Mazurova Y, Adamcova M, et al. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol Res. 2005b;51:223–231. PubMed

Simunek T, Sterba M, Holeckova M, Kaplanova J, Klimtova I, Adamcova M, et al. Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals. 2005c;18:163–169. PubMed

Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med. 1998;339:900–905. PubMed

Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol. 2001;67:30–34. PubMed

Tannock I, Guttman P. Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer. 1981;43:245–248. PubMed PMC

Tenopoulou M, Doulias PT, Barbouti A, Brunk U, Galaris D. Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apoptosis. Biochem J. 2005;387:703–710. PubMed PMC

Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27:502–522. PubMed

Van Acker FAA, Van Acker SABE, Kramer K, Haenen GRMM, Bast A, Van der Vijgh WJF. 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res. 2000;6:1337–1341. PubMed

Van Acker SABE, Boven E, Kuiper K, Van den Berg DJ, Grimbergen JA, Kramer K, et al. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997;3:1747–1754. PubMed

Van Acker SABE, Van Balen GP, Van den Berg DJ, Bast A, Van der Vijgh WJF. Influence of iron chelation on the antioxidant activity of flavonoids. Biochem Pharmacol. 1998;56:935–943. PubMed

Van Acker SABE, Van den Berg DJ, Tromp MN, Griffioen DH, Van Bennekom WP, Van der Vijgh WJF, et al. Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med. 1996;20:331–342. PubMed

Wu X, Hasinoff BB. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs. 2005;16:93–99. PubMed

Wu X, Patel D, Hasinoff BB. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin. J Inorg Biochem. 2004;98:1818–1823. PubMed

Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 2005;68:261–271. PubMed

Yarali N, Fisgn T, Duru F, Kara A, Ecin N, Fitoz S, et al. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion. J Pediatr Hematol Oncol. 2006;28:11–16. PubMed

Zhang J, Clark JR, Jr, Herman EH, Ferrans VJ. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Moll Cell Cardiol. 1996;28:1931–1943. PubMed

Zhou S, Palmeira CM, Wallace KB. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett. 2001;121:151–157. PubMed

MicroRNAs in doxorubicin-induced cardiotoxicity: The DNA damage response

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death

Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone